ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,628Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 78

$484K Total Retail Price of All Prescriptions

Rank: 3 out of 78

353 Patients Receiving at Least One Drug in Part D
64%Patients 65 Years and Older
75% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in District of Columbia
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 353 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

7% of this provider’s 353 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

2% of this provider’s 5,754 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in District of Columbia
LISINOPRIL 417 299 1 1
SIMVASTATIN 340 252 2 3
AMLODIPINE BESYLATE 338 269 3 2
METFORMIN HCL 275 206 4 5
HYDROCHLOROTHIAZIDE 247 159 5 4
FUROSEMIDE 207 133 6 7
PRAVASTATIN SODIUM 185 120 7 11
LEVOTHYROXINE SODIUM 159 158 8 15
METOPROLOL SUCCINATE 159 124 8 12
LOSARTAN-HYDROCHLOROTHIAZIDE 155 114 10 24
ATORVASTATIN CALCIUM 154 121 11 8
TRAMADOL HCL 142 98 12 28
GABAPENTIN 139 88 13 14
TRIAMTERENE-HCTZ 131 109 14 20
KLOR-CON M20 124 108 15 34
FLUTICASONE PROPIONATE 117 51 16 31
OMEPRAZOLE 113 65 17 6
LISINOPRIL-HYDROCHLOROTHIAZIDE 108 66 18 21
CARVEDILOL 102 57 19 23
PANTOPRAZOLE SODIUM 100 66 20 63
VERAPAMIL ER 99 96 21 61
ACETAMINOPHEN-CODEINE 97 67 S3 22 22
JANUVIA 95 77 23 58
ATENOLOL 93 72 24 10
OXYCONTIN 92 26 S2 25 84
METOPROLOL TARTRATE 91 85 26 9
LOVASTATIN 90 73 27 25
CLOPIDOGREL 88 54 28 44
ZOLPIDEM TARTRATE 86 63 29 62
NEXIUM 85 47 30 38
LOSARTAN POTASSIUM 85 65 30 13
DIOVAN HCT 78 54 32 53
SINGULAIR 76 37 33 54
CLONIDINE HCL 75 27 34 37
PLAVIX 74 57 35 55
DIOVAN 72 62 36 29
VENTOLIN HFA 64 26 37 35
NIFEDIPINE ER 64 39 37 26
INSULIN SYRINGE 57 42 39 39
NAPROXEN 55 41 40 17
HYDRALAZINE HCL 53 41 41 48
MONTELUKAST SODIUM 52 22 42 82
CRESTOR 50 49 43 51
ZETIA 50 26 43 111
ALENDRONATE SODIUM 50 49 43 50
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 30, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.